208 related articles for article (PubMed ID: 36073343)
1. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study.
Bassegoda O; Rivera-Esteban J; Serra I; Morillas R; Broquetas T; Vergara M; Rodriguez A; Aracil C; Virolés S; Carrión JA; Pardo A; Rodríguez-Tajes S; Serra-Burriel M; Pericàs JM; Augustin S; Ginès P; Graupera I
Hepatol Commun; 2022 Nov; 6(11):3212-3222. PubMed ID: 36073343
[TBL] [Abstract][Full Text] [Related]
2. Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis.
Navadurong H; Thanapirom K; Wejnaruemarn S; Prasoppokakorn T; Chaiteerakij R; Komolmit P; Treeprasertsuk S
World J Gastroenterol; 2023 Aug; 29(32):4873-4882. PubMed ID: 37701131
[TBL] [Abstract][Full Text] [Related]
3. Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.
Liu TL; Trogdon J; Weinberger M; Fried B; Barritt AS
Dig Dis Sci; 2016 Nov; 61(11):3335-3345. PubMed ID: 27480088
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
[TBL] [Abstract][Full Text] [Related]
5. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
6. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.
Huang DQ; Noureddin N; Ajmera V; Amangurbanova M; Bettencourt R; Truong E; Gidener T; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Yoneda M; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Allen AM; Noureddin M; Loomba R
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):829-836. PubMed ID: 37419133
[TBL] [Abstract][Full Text] [Related]
7. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
Allen AM; Therneau TM; Ahmed OT; Gidener T; Mara KC; Larson JJ; Canning RE; Benson JT; Kamath PS
J Hepatol; 2022 Nov; 77(5):1237-1245. PubMed ID: 35843374
[TBL] [Abstract][Full Text] [Related]
8. Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg.
Jindal A; Bhardwaj A; Kumar G; Sarin SK
Am J Gastroenterol; 2020 Oct; 115(10):1624-1633. PubMed ID: 32453061
[TBL] [Abstract][Full Text] [Related]
9. Patients with liver cirrhosis show worse survival if decompensation occurs later during course of disease than at diagnosis.
Nilsson E; Anderson H; Sargenti K; Lindgren S; Prytz H
Scand J Gastroenterol; 2018 Apr; 53(4):475-481. PubMed ID: 29513096
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
[TBL] [Abstract][Full Text] [Related]
11. Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis.
Wiegand J; Kühne M; Pradat P; Mössner J; Trepo C; Tillmann HL
Aliment Pharmacol Ther; 2012 Jun; 35(12):1443-50. PubMed ID: 22530565
[TBL] [Abstract][Full Text] [Related]
12. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
[TBL] [Abstract][Full Text] [Related]
13. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.
Orman ES; Roberts A; Ghabril M; Nephew L; Desai AP; Patidar K; Chalasani N
JAMA Netw Open; 2019 Jun; 2(6):e196412. PubMed ID: 31251379
[TBL] [Abstract][Full Text] [Related]
14. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
[TBL] [Abstract][Full Text] [Related]
15. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.
Kaplan DE; Mehta R; Garcia-Tsao G; Albrecht J; Aytaman A; Baffy G; Bajaj J; Hernaez R; Hunt K; Ioannou G; Johnson K; Kanwal F; Lee TH; Monto A; Pandya P; Schaubel D; Taddei TH
Contemp Clin Trials; 2021 May; 104():106367. PubMed ID: 33771685
[TBL] [Abstract][Full Text] [Related]
16. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients.
D'Amico G; Pasta L; Morabito A; D'Amico M; Caltagirone M; Malizia G; Tinè F; Giannuoli G; Traina M; Vizzini G; Politi F; Luca A; Virdone R; Licata A; Pagliaro L
Aliment Pharmacol Ther; 2014 May; 39(10):1180-93. PubMed ID: 24654740
[TBL] [Abstract][Full Text] [Related]
17. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature.
Almomani A; Kumar P; Onwuzo S; Boustany A; Krishtopaytis E; Hitawala A; Alshaikh D; Albakri A; Hussein L; Hussein E; Asaad I
J Gastroenterol Hepatol; 2023 Feb; 38(2):269-273. PubMed ID: 36328950
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Risk of Further Decompensation and Survival in Patients With Cirrhosis With Variceal Bleeding as Their First Decompensation Event.
Gupta A; Rana R; Agarwal S; Sharma S; Gopi S; Mohta S; Gunjan D; Saraya A
Am J Gastroenterol; 2023 May; 118(5):833-839. PubMed ID: 36114777
[TBL] [Abstract][Full Text] [Related]
20. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
